Headache News and Research

Latest Headache News and Research

Headaches, back pain and arthritis cost companies more than $61 billion per annum

Headaches, back pain, arthritis and other aches distract employees and cost companies more than $61 billion a year in lost productive time, according to a study published in the Journal of the American Medical Association.

1 Oct 2010

APhA urges consumers to discuss proper medication usage with pharmacists

In honor of American Pharmacists Month, the American Pharmacists Association (APhA) encourages consumers to hold an open dialogue with their pharmacists about a growing problem in the United States, the proper usage of and adherence to medications.

1 Oct 2010

Neurologic Clinics journal publishes latest advances in neurologic disorders

The latest advances in treating neurologic disorders such as stroke, headache, Parkinson's disease, epilepsy and sleep disorders are detailed in a special issue of the journal Neurologic Clinics.

1 Oct 2010

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Results from a randomized, double-blinded, placebo-controlled, multicentred study just published in the Journal of Drugs in Dermatology shows that treating Actinic Keratoses (AK) with imiquimod 3.75% (Zyclara®) following cryotherapy was more effective than cryotherapy alone in reducing total AK lesion count and achieving complete clearance of AK.

30 Sep 2010

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Baxter International Inc. today announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults and the elderly. PREFLUCEL is manufactured using Baxter's proprietary advanced Vero cell technology.

From Baxter International Inc. 30 Sep 2010

Ready-to-Use Cardene I.V. lowers acutely elevated blood pressure: CLUE study

Results from the CLUE study, a head-to-head comparison between Ready-to-Use Cardene I.V. (nicardipine) and labetalol in the emergency room, showed that Ready-to-Use Cardene I.V. lowers acutely elevated blood pressure more effectively than labetalol. These data were presented today at the annual meeting of the American College of Emergency Physicians (ACEP) in Las Vegas, Nevada.

29 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

Study indicates majority of children suffering from chronic headache may outgrow the condition

Most children who suffer from chronic daily headache may outgrow the disabling condition, according to research published in the July 15, 2009, online issue of NeurologyÂ®, the medical journal of the American Academy of Neurology.

28 Sep 2010

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic low back pain have been published online by Expert Opinion on Pharmacotherapy. In addition, this study compared oxycodone controlled-release (CR) to placebo as an active control.

28 Sep 2010

Bayer’s new oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved a new oral contraceptive, Beyaz (drospirenone / ethinyl estradiol / levomefolate calcium tablets and levomefolate calcium tablets).

28 Sep 2010

Scientists identify gene associated with common migraines

An international study led by scientists at Universit- de Montr-al and University of Oxford, has identified a gene associated with common migraines. Their findings show that a mutation in the KCNK18 gene inhibits the function of a protein called TRESK. TRESK normally plays a key role in nerve cell communication. Published today in Nature Medicine, this study may have implications for people who suffer from recurrent headaches, which include more than six million Canadians.

28 Sep 2010

Clinical Data announces Stedivaze agonist data at ASNC2010 meeting

Clinical Data, Inc., today presented data from Phase I studies of Stedivaze (apadenoson), which demonstrated overall safety and tolerability in patients with asthma and chronic obstructive pulmonary disease (COPD).

27 Sep 2010

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.

27 Sep 2010

FDA approves OZURDEX implant for uveitis treatment

Allergan, Inc. today announced that the United States Food and Drug Administration (FDA) has approved OZURDEX (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye.

27 Sep 2010

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Following today’s announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals Europe Limited underscore the company’s commitment to ACTOS® (pioglitazone HCl) and ACTOS-containing medications, and to the millions of people living with type 2 diabetes.

24 Sep 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

Biogen Idec concurs with FDA on safety monitoring for Gilenya through REMS

Biogen Idec is committed to improving the lives of people with multiple sclerosis (MS), and no company is doing more for these patients. There has been a desire within the MS community for an oral treatment for a long time, and the approval of Gilenya has made this a reality.

23 Sep 2010

FDA approves Gilenya capsules for reducing MS relapses

The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).

22 Sep 2010

Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD

New Phase III data found that investigational linagliptin therapy resulted in significant reductions in blood sugar as measured by hemoglobin A1c (HbA1c) when compared to placebo, both when added to sulfonylurea (SU) in inadequately controlled type 2 diabetes (T2D) patients, and when administered as monotherapy in T2D patients for whom metformin is inappropriate.

22 Sep 2010

High dose aspirin effective for treatment of severe headache and migraine

An inexpensive, hundred-year-old therapy for pain - aspirin - is effective in high doses for the treatment of severe headache and migraine caused by drug withdrawal, according to a new study by researchers with the UCSF Headache Center. Study participants were administered aspirin through an IV and 25 percent of the time they reported a significant reduction in pain - three points on the 10-point pain scale.

22 Sep 2010

Headache News and Research

Latest Headache News and Research

Headaches, back pain and arthritis cost companies more than $61 billion per annum

APhA urges consumers to discuss proper medication usage with pharmacists

Neurologic Clinics journal publishes latest advances in neurologic disorders

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Ready-to-Use Cardene I.V. lowers acutely elevated blood pressure: CLUE study

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Study indicates majority of children suffering from chronic headache may outgrow the condition

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Bayer’s new oral contraceptive receives FDA approval

Scientists identify gene associated with common migraines

Clinical Data announces Stedivaze agonist data at ASNC2010 meeting

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

FDA approves OZURDEX implant for uveitis treatment

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

Biogen Idec concurs with FDA on safety monitoring for Gilenya through REMS

FDA approves Gilenya capsules for reducing MS relapses

Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD

High dose aspirin effective for treatment of severe headache and migraine

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Headache News and Research

Latest Headache News and Research

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in